CA3240138A1 - Nap for sex-specific treatment of diseases - Google Patents
Nap for sex-specific treatment of diseases Download PDFInfo
- Publication number
- CA3240138A1 CA3240138A1 CA3240138A CA3240138A CA3240138A1 CA 3240138 A1 CA3240138 A1 CA 3240138A1 CA 3240138 A CA3240138 A CA 3240138A CA 3240138 A CA3240138 A CA 3240138A CA 3240138 A1 CA3240138 A1 CA 3240138A1
- Authority
- CA
- Canada
- Prior art keywords
- day
- pharmaceutical composition
- disease
- subject
- nap
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Zoology (AREA)
- Otolaryngology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163289174P | 2021-12-14 | 2021-12-14 | |
| US63/289,174 | 2021-12-14 | ||
| US202263306146P | 2022-02-03 | 2022-02-03 | |
| US63/306,146 | 2022-02-03 | ||
| PCT/IL2022/051314 WO2023112025A1 (en) | 2021-12-14 | 2022-12-13 | Nap for sex-specific treatment of diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3240138A1 true CA3240138A1 (en) | 2023-06-22 |
Family
ID=86773996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3240138A Pending CA3240138A1 (en) | 2021-12-14 | 2022-12-13 | Nap for sex-specific treatment of diseases |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250312408A1 (https=) |
| EP (1) | EP4447994A4 (https=) |
| JP (1) | JP2025501458A (https=) |
| KR (1) | KR20240135692A (https=) |
| AU (1) | AU2022410066A1 (https=) |
| CA (1) | CA3240138A1 (https=) |
| IL (1) | IL313226A (https=) |
| MX (1) | MX2024006777A (https=) |
| WO (1) | WO2023112025A1 (https=) |
-
2022
- 2022-12-13 WO PCT/IL2022/051314 patent/WO2023112025A1/en not_active Ceased
- 2022-12-13 AU AU2022410066A patent/AU2022410066A1/en active Pending
- 2022-12-13 CA CA3240138A patent/CA3240138A1/en active Pending
- 2022-12-13 IL IL313226A patent/IL313226A/en unknown
- 2022-12-13 EP EP22906851.5A patent/EP4447994A4/en active Pending
- 2022-12-13 MX MX2024006777A patent/MX2024006777A/es unknown
- 2022-12-13 JP JP2024533944A patent/JP2025501458A/ja active Pending
- 2022-12-13 US US18/718,925 patent/US20250312408A1/en active Pending
- 2022-12-13 KR KR1020247022758A patent/KR20240135692A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4447994A1 (en) | 2024-10-23 |
| IL313226A (en) | 2024-07-01 |
| WO2023112025A1 (en) | 2023-06-22 |
| AU2022410066A1 (en) | 2024-07-25 |
| MX2024006777A (es) | 2024-08-06 |
| KR20240135692A (ko) | 2024-09-11 |
| JP2025501458A (ja) | 2025-01-22 |
| US20250312408A1 (en) | 2025-10-09 |
| EP4447994A4 (en) | 2026-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hampel et al. | The amyloid-β pathway in Alzheimer’s disease | |
| Curcio-Morelli et al. | Macroautophagy is defective in mucolipin-1-deficient mouse neurons | |
| Solesio et al. | Carbonic anhydrase inhibition selectively prevents amyloid β neurovascular mitochondrial toxicity | |
| Rahman et al. | Therapeutic implication of autophagy in neurodegenerative diseases | |
| Vilchez et al. | The role of protein clearance mechanisms in organismal ageing and age-related diseases | |
| Valerio et al. | NF‐κB pathway: a target for preventing β‐amyloid (Aβ)‐induced neuronal damage and Aβ42 production | |
| Busciglio et al. | Altered metabolism of the amyloid β precursor protein is associated with mitochondrial dysfunction in Down's syndrome | |
| Abe et al. | Alteration of 8-hydroxyguanosine concentrations in the cerebrospinal fluid and serum from patients with Parkinson's disease | |
| Jaliffa et al. | Sirt1 involvement in rd10 mouse retinal degeneration | |
| Sharma et al. | Identification of LOXL1 protein and Apolipoprotein E as components of surgically isolated pseudoexfoliation material by direct mass spectrometry | |
| Wang et al. | Ursolic acid ameliorates amyloid β-induced pathological symptoms in Caenorhabditis elegans by activating the proteasome | |
| Chu et al. | Gamma secretase-activating protein is a substrate for caspase-3: implications for Alzheimer’s disease | |
| Tran et al. | Chronic psychosocial stress triggers cognitive impairment in a novel at-risk model of Alzheimer's disease | |
| Zhang et al. | Death-associated protein kinase 1 as a therapeutic target for Alzheimer's disease | |
| US20180217163A1 (en) | Treatment of neurodegenerative conditions using pkc activators after determining the presence of the apoe4 allele | |
| Olsson et al. | Imatinib treatment and Aβ42 in humans | |
| Singulani et al. | Mini review: Mitochondrial dysfunction in Alzheimer's disease: Therapeutic implications of lithium | |
| Straten et al. | Influence of lithium treatment on GDNF serum and CSF concentrations in patients with early Alzheimer's disease | |
| Ma et al. | Diabetes influences the fusion of autophagosomes with lysosomes in SH-SY5Y cells and induces Aβ deposition and cognitive dysfunction in STZ-induced diabetic rats | |
| Xiao | Levetiracetam might act as an efficacious drug to attenuate cognitive deficits of Alzheimer’s disease | |
| US20250312408A1 (en) | Nap for sex-specific treatment of diseases | |
| Wojsiat et al. | Familial Alzheimer’s disease lymphocytes respond differently than sporadic cells to oxidative stress: upregulated p53-p21 signaling linked with presenilin 1 mutants | |
| Heredia et al. | Deposition of amyloid fibrils promotes cell-surface accumulation of amyloid β precursor protein | |
| HK40117549A (zh) | 用於疾病的性别特异性治疗的nap | |
| Di Lucente et al. | The impact of mild episodic ketosis on microglia and hippocampal long‐term depression in 5xFAD mice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20240924 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250122 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED Effective date: 20250122 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250610 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250610 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251027 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251211 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251211 |